Search the Newsreel

Where Food Comes From Inc (WFCF) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Where Food Comes From Inc (WFCF), indicating a current risk score of 3.41, ranking it 308 out of 486 in the Software & IT Services industry. The company's beta of 0.10 suggests it tends to underperform in …

Prominence Energy Advances SA Helium and Hydrogen Portfolio With Strong Quarter

ANF|Abercrombie & Fitch Co|Kurs:108.580|Änderung %:+9.040

TOROMONT ANNOUNCES RESULTS FOR THE SECOND QUARTER OF 2026 AND QUARTERLY DIVIDEND

TORONTO, July 28, 2026 /CNW/ -- Toromont Industries Ltd. (TSX: TIH) today reported its financial results for the second quarter ended June 30, 2026.Toromont Industries Ltd. Logo Three months ended June 30 Six months ended June 30 ($ millions, except per share amounts) 2026 …

ANF (ANF) insider Scott D. Lipesky plans $1.05M Class A share sale

Scott D. Lipesky, an insider at Abercrombie & Fitch (ANF), has filed a notice to sell 10,000 Class A shares valued at approximately $1,050,000 through Fidelity Brokerage Services LLC, starting on or after July 28, 2026. These shares originated from restricted stock vesting in …

ProMIS jumps on trial data for Alzheimer’s drug (PMN:NASDAQ)

ProMIS Neurosciences (PMN) share price increased following the release of interim data from an early-stage trial for its Alzheimer's drug, PMN310. The positive results led Guggenheim to raise its price target for the Canadian company.

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss 6-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer's disease. Key Opinion Leaders Dr. Will Mantyh and Dr. Michael Weiner will join company leadership to review …

ProMIS Alzheimer's Drug Shows Strong Safety Profile Midway Through Trial

ProMIS Neurosciences' Alzheimer's drug, PMN310, has shown a strong safety profile midway through its Phase 1 clinical trial. The study found no evidence of amyloid-related imaging abnormalities (ARIA), a common side effect in other amyloid-targeting Alzheimer's treatments. This positive safety data suggests PMN310 could …

Should Value Investors Buy Abercrombie & Fitch (ANF) Stock?

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends …

Abercrombie & Fitch Company (ANF) Is a Trending Stock: Facts to Know Before Betting on It

Abercrombie & Fitch (ANF) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this teen clothing retailer have returned …

ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results

ProMIS Neurosciences (NASDAQ: PMN) shares rose 13% after reporting positive six-month interim safety and biomarker data from its PRECISE-AD Phase 1b study for Alzheimer's treatment PMN310. The study showed a strong safety profile with no serious adverse events and no ARIA-E cases, suggesting the …

ProMIS Neurosciences reports no ARIA‑E and favorable 6‑month biomarker trends for PMN310; 12‑month topline due Q1 2027

ProMIS Neurosciences released a six-month interim report for PMN310, showing no ARIA-E and low total ARIA (4.4%), with favorable biomarker trends. The trial is blinded and ongoing, with unblinded 12-month topline results, including efficacy data, anticipated in Q1 2027. PMN310 is designed to specifically …

ProMIS Neurosciences stock jumps on trial safety data

ProMIS Neurosciences Inc. (NASDAQ:PMN) stock jumped 13% after reporting positive blinded six-month interim safety and biomarker data for PMN310 in its PRECISE-AD Phase 1b Alzheimer’s disease trial. The trial showed no amyloid-related imaging abnormalities-edema (ARIA-E) and low levels of ARIA-H, with no serious adverse …

ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data

ProMIS Neurosciences (Nasdaq: PMN) announced positive blinded six-month interim safety and biomarker data from its Phase 1b PRECISE-AD trial for PMN310 in early Alzheimer's disease. The data showed a favorable safety profile with no ARIA-E cases and a low rate of total ARIA, even …

Why Did Toromont Industries Ltd. (TSX:TIH) Stock Plunge 6.71% on 27 July 2026?

Why Toromont Industries (TSX:TIH) Shares Came Under Pressure?

Where Food Comes From (NASDAQ:WFCF) Stock Price Passes Above 50-Day Moving Average - Here's Why

Grupo Aeromexico SAB de CV (AERO) Income Statement

This article provides access to the annual and quarterly income statements for Grupo Aeromexico SAB de CV (AERO) on TradingKey. It also includes an FAQ section explaining how to read an income statement, the difference between quarterly and annual statements, the meaning of YOY, …

Roma Green Finance Ltd (ROMA) Cash Flow

This article provides an overview of Roma Green Finance Ltd's (ROMA) cash flow statements, including operating, investing, and financing cash flows. It details the company's operating cash flow for fiscal 2025, its year-over-year change, and its latest financing and free cash flow figures. The …

ProMIS Neurosciences Inc (PMN) Income Statement

This article provides the quarterly and annual income statements for ProMIS Neurosciences Inc (PMN), detailing financial performance metrics such as total revenue, operating expenses, and net income. It includes data from FY2012Q1 to FY2026Q1, highlighting negative net income and operating profit over recent periods. …

Roma Green Finance Limited Revenue Breakdown – NASDAQ:ROMA

AERO|Grupo Aeromexico SAB de CV|Price:15.355|Chg%:+0.385

This article provides detailed real-time quotes, market trends, and analysis for Grupo Aeromexico SAB de CV (AERO). It includes key figures like current price, daily changes, market capitalization, and various financial indicators. The page also offers technical indicators and moving averages to help investors …

Roman DBDR Acquisition Corp II

This article provides a company overview of Roman DBDR Acquisition Corp II (DRDB), detailing its market capitalization, P/E ratio, and recent stock performance. It notes that relevant data regarding revenue breakdown by business segment and region has not yet been disclosed by the company.

Where Food Comes From Inc (WFCF) Income Statement

This article provides the quarterly and annual income statements for Where Food Comes From Inc (WFCF), detailing key financial metrics such as total revenue, cost of revenue, operating expenses, operating profit, net income, and basic/diluted earnings per share. It allows users to gain insights …

Two Alzheimer’s researchers join ProMIS webinar on blinded trial data

ProMIS Neurosciences will host a webinar on July 28, 2026, to discuss six-month blinded interim data from its PRECISE-AD Phase 1b trial of PMN310, its lead Alzheimer's candidate. The webinar will feature company executives, Dr. Will Mantyh, and Dr. Michael Weiner, who will discuss …

WFCF|Where Food Comes From Inc|Price:12.050|Chg%:-0.200

Where Food Comes From, Inc. (WFCF) is a company that provides third-party verification of food production practices in North America, supporting a wide range of agricultural and food industry participants. The company operates through two segments: Verification and Certification, which includes on-site and desk …

Where Food Comes From Inc (WFCF) Cash Flow

This article provides a detailed cash flow statement for Where Food Comes From Inc (WFCF), broken down into quarterly and annual figures across operating, investing, and financing activities. It also includes key financial metrics like market cap and P/E ratio, alongside an FAQ section …

Roma Green Finance Ltd (ROMA) Balance Sheet

This article provides the quarterly and annual balance sheets for Roma Green Finance Ltd (ROMA), detailing financial health metrics such as cash and cash equivalents, total assets, liabilities, and shareholders' equity. It allows for the analysis of the company's fundamentals and key financial ratios. …

MEDIROM Healthcare Technologies (MRM) Nears $1.00 Resistance Following 2.08% Gain - Elliott Wave Count

Roman DBDR Acquisition Corp II (DRDB) Cash Flow

This article provides the quarterly and annual cash flow statements for Roman DBDR Acquisition Corp II (DRDB), detailing operating, investing, and financing cash flows from FY2024Q4 to FY2026Q1. It includes financial figures such as net income, changes in working capital, and net cash flows, …

Roman DBDR Acquisition Corp II (DRDB) Balance Sheet

This article provides the detailed balance sheet for Roman DBDR Acquisition Corp II (DRDB), presenting both annual and quarterly financial data. It allows users to assess the company's financial health by analyzing assets, liabilities, and shareholder equity over various periods. The page also includes …

Roman DBDR Acquisition Corp II (DRDB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Roman DBDR Acquisition Corp II (DRDB), focusing on its PE (Price/Earnings) and PB (Price/Book) ratios, and fair value. It lists current stock information including its market capitalization, PE TTM, and current trading price. The content seems to …

Medirom Healthcare Technologies Inc (MRM) Cash Flow

This article presents the cash flow statement for Medirom Healthcare Technologies Inc (MRM), including operating, investing, and financing cash flows, both quarterly and annually. It details various financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. …

PMN|ProMIS Neurosciences Inc|Price:11.655|Chg%:-0.545

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases like Alzheimer's, ALS, and MSA. The company utilizes a proprietary computational platform to identify disease-specific epitopes and has product candidates such as PMN310, PMN267, and PMN442 in development. …

Medirom Healthcare Technologies Inc

This article provides a revenue breakdown for Medirom Healthcare Technologies Inc (MRM), detailing its business segments and regional contributions. The company's revenue streams primarily consist of directly-operated salons, sale of directly-owned salons, sublease revenue, other franchise revenues, royalty income, and other income, all originating …

PMN Initiated Coverage by Chardan Capital -- Rating Set to Buy

Chardan Capital has initiated coverage on ProMIS Neurosciences (PMN) with a Buy rating and a price target of $20.00, suggesting a significant upside from its current trading price of $12.345. Despite a strong financial strength rating of 9/10, PMN holds a low GF Score™ …